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Continuing high vaccination coverage has resulted in dramatic 
decreases in the global incidence of many childhood diseases. The 
Expanded Program on Immunization (EPI) originally included 
vaccines for tuberculosis, diphtheria, tetanus, pertussis, poliomyelitis 
and measles, but others including hepatitis B (HB) and Haemophilus 
influenzae type b (Hib) have since been added. In South Africa, HB 
and Hib conjugate vaccines were added to the national schedule in 
1995 and 1999, respectively; conjugated pneumococcal and rotavirus 
vaccines were introduced in 2008 and inactivated poliovirus vaccine 
(IPV) was added in 2009. In response to increasing childhood 
vaccinations, combination vaccines, typically including acellular 
pertussis (aP), IPV, and others such as Hib and/or HB have been 
licensed over the last 10 years, and are now used in national 
immunisation programmes worldwide.1
Combined vaccines facilitate high coverage and reduce 
administration costs.2 The aP components included in many 
combined vaccines consist of purified Bordetella pertussis antigens 
that are better tolerated than the traditional whole-cell pertussis (wP) 
vaccines, and have satisfactory immunogenicity and protection.3 
Based on their protective efficacy and improved safety and 
reactogenicity, the World Health Organization (WHO) recommends 
aP vaccines for primary vaccination, and a booster dose preferably 
during the second year of life.4
Sanofi Pasteur has developed a DTaP-IPV liquid combination 
vaccine used to reconstitute a lyophilised tetanus protein-conjugated 
Hib capsular polysaccharide vaccine (PRP~T) at the time of injection. 
The PRP~T vaccine is licensed as ActHib in South Africa and 
worldwide. The IPV vaccine is also licensed worldwide as Imovax 
Polio, and both are WHO pre-qualified.5 This DTaP-IPV//PRP~T 
combination vaccine, first licensed in 1997 as Pentaxim or Pentavac, is 
now licensed in over 100 countries. It was added to the EPI schedule 
(6, 10 and 14 weeks of age) in South Africa in April 2009. Its safety and 
immunogenicity have been assessed in numerous clinical studies.6 The 
approved indication is for a three-dose primary immunisation and a 
booster vaccination during the second year of life.
According to the WHO, all available aP-containing vaccines 
have demonstrated high levels of effectiveness in preventing 
pertussis, irrespective of antigen content.4 The effectiveness of the aP 
vaccine used in this study has been confirmed by national pertussis 
surveillance in Sweden7 and surveillance data are available from 
Austria and France.8,9
We reported the immunogenicity and safety of the DTaP–IPV//
PRP~T combined vaccine given as a primary vaccination at 6, 10 
and 14 weeks of age in South Africa.10 The present study assessed the 
immunogenicity and safety of the same vaccine given as a booster to 
the same group of children at 18 - 19 months of age.
Methods 
Study design and participants
This Phase III, open clinical trial (clinicaltrials.gov ID NCT00254969) 
was conducted at the Chris Hani Baragwanath Hospital, Johannesburg, 
South Africa. The protocol was approved by the University of the 
Witwatersrand Human Research Ethics Committee (HREC) and the 
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Objective. To assess the immunogenicity and safety of a pentavalent 
diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Hib 
polysaccharide-conjugate vaccine booster.
Design, setting and participants. A DTaP-IPV//PRP~T vaccine 
(Pentaxim, a Sanofi Pasteur AcXim family vaccine) was given 
to 182 healthy children in South Africa at 18 - 19 months of 
age following priming with the same vaccine plus a monovalent 
hepatitis B vaccine at 6, 10 and 14 weeks of age.
Outcome measures. Seroprotection (SP) and seroconversion (SC) 
rates, geometric mean titres (GMTs) and concentrations (GMCs) 
were assessed before, and 1 month after, the booster dose. Safety 
was assessed using parental reports.
Results. One month after primary vaccination, at least 94.3% 
of participants were seroprotected against tetanus (≥0.01 IU/ml), 
diphtheria (≥0.01 IU/ml), poliovirus (≥8 1/dil) and Haemophilus 
influenzae type b (Hib) infection (≥0.15 µg/ml). Before the booster 
dose, the SP rates ranged from 65.7% to 100%. One month after 
the booster dose, SP rates were 97.7% for Hib (anti-PRP titre ≥1.0 
µg/ml), 100.0% for diphtheria (≥0.1 IU/ml) and 100% for tetanus 
(≥0.1 IU/ml) and poliovirus types 1, 2, 3 (≥8 1/dil). At least 95.7% 
of participants had fourfold post-booster increases in anti-pertussis 
antibody titres. GMTs increased from 11.21 to 465.51 EU/ml and 
from 12.89 to 520.35 EU/ml for anti-PT and anti-FHA respectively. 
Anti-PRP GMT increased from 0.35 to 47.01 µg/ml. The DTaP-
IPV//PRP~T vaccine booster was well tolerated, with fever ≥39.0°C 
in only 1.7% of participants.
Conclusions. Antibody persistence following priming was 
satisfactory. The pentavalent DTaP-IPV//PRP~T vaccine booster 
was highly immunogenic and well tolerated.
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Medicines Control Council (MCC) and conducted in accordance with 
guidelines of the Declaration of Helsinki, the International Conference 
on Harmonization (ICH) and Good Practice in the Conduct of Clinical 
Trials in Human Participants in South Africa. Participants’ parents or 
legal guardians gave written informed consent.
Healthy full-term (≥37 weeks) infants of birthweight ≥2 500 g had 
previously been sequentially screened and enrolled during the first 24 
hours of life to receive a primary series vaccination with the DTaP-
IPV//PRP~T vaccine, plus a concomitant monovalent HB vaccine, 
at 6, 10 and 14 weeks of age. Infants whose mothers were known 
to be seropositive for HIV were excluded from the study before the 
primary series vaccination. Participants who had completed the 
primary series vaccination were eligible to receive a booster dose of 
the same vaccine at 18 - 19 months of age.
Vaccines
The composition of each 0.5  ml dose of the combined DTaP-IPV//
PRP~T vaccine (Pentaxim, Sanofi Pasteur, France, batch number A2053) 
has been described elsewhere.6 The PRP~T was supplied as a freeze-dried 
powder and reconstituted with the DTaP-IPV vaccine liquid suspension 
at the time of injection. The vaccine was administered intramuscularly 
into the anterolateral aspect of the right upper thigh.
Safety and reactogenicity
The investigator monitored participants for immediate adverse reactions 
in the 30 minutes following each vaccine injection. Parents or legal 
representatives recorded time of onset, duration, and severity of solicited 
injection site (tenderness, redness, swelling) and systemic reactions 
(axillary temperature ≥37.4°C, vomiting, abnormal crying, drowsiness, 
loss of appetite, irritability) for the following 7 days. Unsolicited adverse 
reactions were recorded from each vaccination until the following study 
visit. Serious adverse events (SAEs) were recorded throughout the study 
period. The investigators evaluated all AEs.
Serology
Blood samples were collected for antibody measurement just before 
and 1 month after the booster vaccination. Serological analyses were 
performed at Sanofi Pasteur’s Global Clinical Immunology laboratory 
in the USA following completion of the booster vaccination. The 
methodologies are described in the primary series article.10
The pre-defined serological correlates of seroprotection (SP) 
were: anti-diphtheria and anti-tetanus ≥0.01 (proxy of short-term 
protection) and ≥0.1 IU/ml (proxy of long-term protection), anti-
poliovirus ≥8 reciprocal dilution (1/dil), anti-PRP ≥0.15  (proxy 
of short-term protection) and ≥1.0  µg/ml (proxy of long-term 
protection), and anti-hepatitis B surface antigen (HBsAg) ≥10 mIU/
ml. Seroconversion (SC) to anti-pertussis antigens was defined as a 
≥ fourfold increase in anti-PT or anti-FHA titre (EU/ml) from pre- to 
post-booster vaccination, since a correlation between antibody level 
and protection against pertussis is not currently well established.11
Statistical methods
The objectives were to determine the SP rates for diphtheria, tetanus, 
poliovirus and PRP before and 1 month after the booster, the SC 
rates for PT and FHA 1 month after the booster vaccination, and to 
describe the safety of the booster vaccination. The statistical analysis 
was descriptive; no hypothesis was tested. For the evaluation of 
immunogenicity, SP and SC rates were calculated with their 95% 
confidence intervals (CIs) by the exact binomial Clopper-Pearson 
method.12 Geometric mean antibody concentrations (GMCs – for 
diphtheria, tetanus, PT, FHA, and PRP) and titres (GMTs – for polio 1, 
2, and 3) were calculated with 95% CIs using the normal approximation 
method.13 Pre- to post-booster GMC and GMT ratios (GMRs) were 
also calculated with 95% CIs. Reverse cumulative distribution curves 
(RCDCs) were constructed for each antibody response. For the 
evaluation of reactogenicity, the number and percentage of participants 
with solicited symptoms after the booster were calculated. Participants 
who received the booster dose and had at least one antibody titration 
were included in the immunogenicity analysis. All participants who 
received the booster were included in the safety analysis.
Results 
Participant disposition
Of 207 participants who completed the primary vaccination series, 
182 (87.9%) received the booster injection. A total of 179 participants 
completed the booster phase. Three participants withdrew because of 
non-compliance with the protocol, voluntary withdrawal, and loss to 
follow-up. The percentage of males (52.8%) was slightly higher than 
females (47.2%). The mean age at booster administration was 18.3 
(standard deviation 0.4) months.
Immunogenicity
Tables I and II present the SP/SC rates, GMC/GMT for each vaccine 
antigen, with 95% CIs. At 1 month after primary vaccination (18 
weeks of age), 94.3 - 100% of participants had been seroprotected 
against diphtheria and tetanus (titre ≥0.01 IU/ml), polio  (titre ≥8 
1/dil)), and Hib (anti-PRP ≥0.15 μg/ml); 4-fold increases in anti-
PT and FHA antibody titres were observed in 98.2% and 83.4% of 
participants, respectively. Just before the booster dose at 18 - 19 
months of age, at least 97.2% of the children still had protective 
levels of antibodies to tetanus, diphtheria, and poliovirus; 99.4% had 
anti-HBsAg antibody titres ≥10 mIU/ml. Seroprotective anti-PRP 
antibody concentrations were observed in 65.7% of participants. 
Following booster vaccination, SP rates for diphtheria and tetanus 
(≥0.1 IU/ml) and poliovirus (≥8 1/dil) were 100%; anti-PRP titres 
≥1.0 μg/ml were observed in 97.7% of participants, and at least 95.7% 
of participants had seroconverted (≥400% increase in antibody titre) 
against the PT and FHA antigens.
For anti-PT and anti-FHA, before the booster vaccination 86.0% 
of participants had anti-PT and 85.8% had anti-FHA antibody 
concentrations ≥5 EU/ml. GMCs increased strongly following 
booster administration, from 11.2 to 465.5 EU/ml for anti-PT and 
from 12.8 to 520.3 EU/ml for anti-FHA. Anti-PRP GMC increased 
from 0.35 to 47.0 mg/ml. Similar strong increases were observed for 
polio, diphtheria and tetanus (Table II).
Geometric mean ratios were 39.4 for anti-PT and 40.7 for anti-
FHA (Table II), and were also high for all other antigens. Reverse 
cumulative distribution curves showed large, linear increases in 
antibody titres from pre- to post-booster vaccination (presented for 
anti-PT, anti-FHA, anti-PRP, and anti-polioviruses in Fig. 1).
Reactogenicity and safety
Most solicited reactions (Table III) occurred within 3 days of 
vaccination and resolved within the 8-day reporting period. The most 
frequent reported injection site reaction was tenderness (60.6%). 
Severe injection site reactions were reported by 3.3% (erythema) to 
7.2% (tenderness) of participants. Abnormal crying, appetite loss 
and irritability were the most frequently reported solicited systemic 
reactions (31.7 - 36.1% of participants) followed by fever, drowsiness 
and vomiting (29.4 - 11.7%). Severe systemic reactions were reported 
by fewer than 2% of participants, except for lost appetite (3.3%).
A total of 64 (35.6%) participants experienced at least one 
unsolicited event within 8 days of the booster vaccination. Most were 
systemic events, upper respiratory tract infections in 23 participants 
and cough in 14 participants. Only one participant experienced an 
unsolicited mild injection site adverse event that was considered 
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related to vaccination (injection site haemorrhage) that started on the 
day of injection, and resolved spontaneously in 3 days.
One SAE was reported: an episode of pulmonary tuberculosis 19 
days after the booster injection that was considered by the investigator 
to be unrelated to vaccination. No hypotonic hyporesponsive episodes 
or seizures were reported. There was no case of litigation for any 
solicited reaction, unsolicited event, or SAE.
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Table II. Geometric mean concentrations (GMCs) or titres (GMTs) 1 month after primary, and before and 1 month after booster 
vaccination and post-/pre-booster geometric mean ratios (GMRs)
DTaP-IPV//PRP~T
Post-primary 
GMC or GMT  
(95% CI)
Pre-booster 
GMC or GMT  
(95% CI)
Post-booster  
GMC or GMT  
(95% CI)
Post-/pre-booster 
GMR  
(95% CI)
Anti-diphtheria (IU/ml) 0.90  
(0.82 - 1.00)
0.04  
(0.03 - 0.05)
3.72  
(3.18 - 4.35)
101.10  
(85.58 - 119.45)
Anti-tetanus  (IU/ml) 0.79  
(0.72 - 0.86)
0.17  
(0.15 - 0.20)
9.23  
(8.10 - 10.51)
56.16  
(47.92 - 65.80)
Anti-polio 1 (1/dil) 1 459.62  
(1 219.02 - 1 747.70)
233.85  
(166.86 - 327.73)
8 928.86  
(7 639.93 - 10 435.25)
35.34  
(24.13 - 51.78)
Anti-polio 2 (1/dil) 1 634.12  
(1 343.97 - 1 986.91)
302.95  
(217.92 - 421.16)
6 608.29  
(5 633.61 - 7 751.59)
22.24  
(15.25 - 32.42)
Anti-polio 3 (1/dil) 2 328.15  
(1 882.84 - 2 878.77)
360.10  
(254.69 - 509.15)
12 119.89  
(10 247.37 – 14 334.58)
33.07  
(22.27 - 49.12)
Anti-PRP (mg/ml) 2.26  
(1.79 - 2.86)
0.35  
(0.26 - 0.46)
47.01  
(37.70 - 58.62) 
134.12  
(100.66 - 178.70)
Anti-PT (EU/ml) 390.62  
(359.03 - 424.97)
11.21  
(9.64 - 13.05)
465.51  
(419.47 - 516.61)
39.40  
(33.18 - 46.77)
Anti-FHA (EU/ml)) 160.18  
(143.55 - 178.74)
12.89  
(10.41 - 15.96)
520.35  
(465.28 - 581.95)
40.74  
(33.88 - 48.98)
Anti-HBsAG (mIU/ml) 935.67  
(787.19 - 1 112.16)
248.66  
(209.44 - 295.22) NA NA
DTaP-IPV//PRP~T vaccine at 6, 10 and 14 weeks of age + booster dose at 18 - 19 months of age, and  recombinant hepatitis B vaccine at 6, 10 and 14 weeks of age.
Anti-diphtheria, anti-tetanus, anti-PT, anti-FHA and anti-PRP antibody concentrations were measured by enyme-linked immunosorbent assay; and anti-poliovirus type 1, 2 and 3 antibody titres 
(1/dil) were measured by seroneutralisation. Anti-HBsAg concentrations were measured by the VITROS chemoluminescence ECi/ECiQ Immunodiagnostic System (Ortho Clinical Diagnostics).
95% CI = 95% confidence interval; NA = not applicable (primary series and pre-booster parameter only).
Table I. Seroprotection and seroconversion rates 1 month after primary vaccination, and before and 1 month after booster vaccination
                                                 DTaP-IPV//PRP~T
Post-primary 
(% (95% CI))
Pre-booster  
(% (95% CI))
Post-booster 
(% (95% CI))
Anti-diphtheria ≥0.01 IU/ml 100 (97.9 - 100.0) 95.7 (90.3 - 98.6) 100.0 (97.9 - 100.0)
Anti-diphtheria ≥0.1 IU/ml 100.0 (97.9 - 100.0) 12.8 (7.4 - 20.3) 100.0 (97.9 - 100.0)
Anti-tetanus ≥0.01 IU/ml 100.0 (97.9 - 100.0) 100.0 (97.6 - 100.0) 100.0 (97.9 - 100.0)
Anti-tetanus ≥0.1 IU/ml 100.0 (97.9 - 100.0) 70.9 (62.9 - 78.0) 100.0 (97.9 - 100.0)
Anti-polio 1 ≥8 (1/dil) 100.0 (97.9 - 100.0) 100.0 (97.3 - 100.0) 100.0 (97.8 - 100.0)
Anti-polio 2 ≥8 (1/dil) 99.4 (96.9 - 100.0) 97.2 (93.0 - 99.2) 100.0 (97.9 - 100.0)
Anti-polio 3 ≥8 (1/dil) 100.0 (97.9 - 100.0) 100.0 (97.2 - 100.0) 100.0 (97.8 - 100.0)
Anti-PRP ≥0.15 µg/ml 94.3 (89.7 - 97.2) 65.7 (58.2 - 72.7) 100.0 (97.9 - 100.0)
Anti-PRP ≥1.0 µg/ml 72.0 (64.7 - 78.5) 25.1 (18.9 - 32.2) 97.7 (94.3 - 99.4)
Anti-PT (EU/ml) ≥4-fold increase 98.2 (94.9 - 99.6)*                              98.4 (94.4 - 99.8)†
Anti-FHA (EU/ml) ≥4-fold increase 83.4 (77.1 - 88.6)*                              95.7 (90.8 - 98.4)†
Anti-HBsAg ≥10 mIU/ml 100.0 (97.9 - 100.0) 99.4 (96.7 - 100.0) NA
DTaP-IPV//PRP~T vaccine at 6, 10 and 14 weeks of age + booster dose at 18 - 19 months of age, and  recombinant hepatitis B vaccine at 6, 10 and 14 weeks of age.
*Increase from pre-primary series. 
†Increase from pre-booster.
Rate (%) = percentage of participants with an immune response (seroprotection/seroconversion); 95% CI = 95% confidence interval; NA = not applicable (primary series parameter only).
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Discussion
This study evaluated the immunogenicity, reactogenicity and safety 
of a DTaP-IPV//PRP~T combination vaccine booster at 18 - 19 
months of age. All participants had completed a primary series 
vaccination with the same vaccine at 6, 10 and 14 weeks of age 
concomitant with a monovalent HB vaccine.10 This combination 
vaccine has been evaluated in several other clinical studies.6 To obtain 
long-lasting immunity, booster doses are required, and our observed 
strong booster responses indicate long-lasting protection.6
Decreasing antibody levels between the primary series and booster 
administration has been previously observed with other DTaP- or 
DTwP-combined vaccines.6 In our study, immediately before the 
booster, at least 97.2% of children had protective levels of antibodies 
to tetanus, diphtheria, the 3 poliovirus types, and Hib (PRP). Anti-
PRP antibody concentrations were also observed in the majority 
of children, although SP rates were lower than for other antigens. 
The strong booster response indicated satisfactory priming and a 
strong immune memory response and demonstrated that long-term 
protection can be expected. The persistence of a very high HB SP 
rate of 99.4% provides additional evidence for the compatibility 
of the monovalent HB vaccine that was co-administered with the 
pentavalent vaccine primary series.10
The anti-PRP concentration decreased in the interval between 
primary and booster vaccination. However, the immune memory 
and booster response induced 
by Hib conjugate vaccine 
were comparable to previous 
studies in children primed and 
then boosted in the second 
year of life with combinations 
containing the same DTaP and 
PRP~T vaccine antigens used 
in the study vaccine.6,14 The 
high vaccine effectiveness (VE) 
of DTaP-PRP~T combinations 
against Hib invasive disease has 
been demonstrated in Germany 
in an extensive, 5-year post-
marketing surveillance study. 
The VE was 96.7% for the 
full 3-dose primary series, 
and 98.5% for those receiving 
a booster dose.15 Additional 
surveillance data from Sweden 
show high VE against invasive 
Hib disease, with incidences of 
0.5 per 100 000 in 1997 and 0.16 
per 100 000 in 2008.16
The high VE of Hib-
conjugate vaccines has also 
been shown in South Africa17 
and a number of other African 
countries that follow EPI 
schedules. In Kenya, Ghana, 
Uganda and Malawi there were 
significant decreases in the 
number of cases of invasive Hib 
disease in children under the 
age of 5 years, but especially in 
children under 1 year of age, 
following the introduction of 
the Hib vaccine at 6, 10 and 14 
weeks of age.6 In The Gambia, 
which follows a similar 2-, 3- and 4-month schedule, no cases of 
Hib meningitis were detected 5 years after the introduction of Hib 
conjugate vaccine.18
Resurgence of invasive Hib disease among young children has 
occurred in countries where only a 3-dose primary series of Hib 
vaccine was administered, leading to the addition of a booster dose 
in the second year of life in various countries including South Africa.6
The waning of serum anti-pertussis antibodies following primary 
vaccination and the strong booster responses seen here are well 
documented.6,19 Today, most countries recommend pertussis booster 
doses in the second year of life, the timing of which differs 
between countries.3  The WHO recommends a pertussis booster 
dose for children, preferably during the second year of life, which 
is expected to ensure protection against pertussis for ≥6 years.4 
National surveillance in Sweden following more than a decade of 
routine use demonstrated effective control of pertussis infection 
by DTaP-containing vaccines, including the study vaccine.6,7 These 
Swedish data show that vaccination at 3, 5 and 12 months of age 
resulted in a marked decrease in pertussis incidence compared with 
no vaccination, and that protection has remained high for 5 - 7 years 
after the third (booster) dose, at which time an additional booster 
dose is recommended. Indeed, the importance of the first booster 
has been shown by outbreaks of pertussis in children in countries 
when only primary vaccination has been given routinely.20 Although 
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Fig. 1. Reverse cumulative distribution curves for anti-PR, anti-FHA, anti-PRP, and anti-polio 1, 2, 3 antibodies pre- 
and post-booster vaccination.
883December 2011, Vol. 101, No. 12  SAMJ
the schedule followed in South Africa is different, we believe that the 
available surveillance data are applicable, as high immunogenicity 
has been demonstrated in a range of vaccination schedules that have 
included a booster during the second year of life.6
Immunisation schedules for IPV vary widely among countries but 
generally include 2 or 3 doses in the first year of life and at least one 
booster dose 6 - 12 months after the last dose of the primary series. 
The persistence of anti-polio types 1, 2 and 3 antibody and strong 
IPV booster response observed in our study provide additional 
support for IPV administration in a 6-, 10- and 14-week EPI schedule 
with a booster at 18 - 19 months of age. According to the WHO, the 
possibility of exposure to either wild or vaccine-derived poliovirus 
is a risk in all parts of the world.21 Booster doses of IPV should be 
continued either until long-term antibody persistence has been 
demonstrated without additional doses after the second year of life, 
or until better worldwide control is achieved.22 Inclusion of IPV in a 
DTaP combination vaccine, as in South Africa, assures vaccination 
coverage as high as that for pertussis primary vaccination.
As expected for childhood combination vaccines, the incidence 
of common, solicited adverse reactions tended to be slightly higher 
for the booster dose compared with the primary vaccination.6 The 
overall reactogenicity of the study vaccine booster was satisfactory.
Booster vaccinations during the second year of life are recommended 
in many countries, including South Africa, to increase the duration 
of protection and reduce the burden of childhood infectious diseases. 
This study confirms that pre-booster antibody titres were satisfactory 
following an accelerated EPI priming schedule. The Pentaxim booster 
at 18 - 19  months of age was well tolerated and induced high 
antibody responses to all the vaccine antigens, indicative of long-term 
protection against each of the five diseases.
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Table III. Participants with solicited injection site or systemic 
reactions within 8 days of the booster dose
DTaP-IPV// PRP~T
Severity n/N % (95% CI)
Injection site reactions
Tenderness Any 109/180 60.6 (53.0 - 67.7)
Severe 13/180 7.2 (3.9 - 12.0)
Erythema Any 71/180 39.4 (32.3 - 47.0)
Severe 6/180 3.3 (1.2 - 7.1)
Swelling Any 71/180 39.4 (32.3 - 47.0)
Severe 7/180 3.9 (1.6 - 7.8)
Systemic reactions
Fever Any 53/180 29.4 (22.9 - 36.7)
Severe 3/180 1.7 (0.3 - 4.8)
Vomiting Any 21/180 11.7 (7.4 - 17.3)
Severe 2/180 1.1 (0.1 - 4.0)
Abnormal crying Any 65/180 36.1 (29.1 - 43.6)
Severe 3/180 1.7 (0.3 - 4.8)
Drowsiness Any 47/180 26.1 (19.9 - 33.2)
Severe 2/180 1.1 (0.1 - 4.0)
Lost appetite Any 59/180 32.8 (26.0 - 40.2)
Severe 6/180 3.3 (1.2 - 7.1)
Irritability Any 57/180 31.7 (24.9 - 39.0)
Severe 2/180 1.1 (0.1 – 4.0)
DTacP-IPV//PRP~T vaccine at 18 - 19 months of age. 
Any = all cases, irrespective of intensity; Any fever = axillary temperature ≥37.40C; Severe 
= number of participants with at least one particular symptom recorded as severe (pain 
‘severe’ = child cries when injected limb is moved or the movement of the injected limb is 
reduced; redness/swelling ‘severe’ = longest diameter was ≥5 cm; fever ‘severe’ = axillary 
temperature ≥39.00C; irritability ‘severe’ = child ‘inconsolable’; drowsiness ‘severe’ = sleeping 
most of the time or difficult to wake up; appetite lost ‘severe’ = refuses ≥3 feeds/meals or 
refuses most feeds/meals; crying abnormal ‘severe’ = more than 3 hours; vomiting ‘severe’ = 
≥6 episodes per 24 hours or requiring parenteral hydration).
